201 related articles for article (PubMed ID: 11990407)
1. Alterations in lipoprotein composition in peritoneal dialysis patients.
Moberly JB; Attman PO; Samuelsson O; Johansson AC; Knight-Gibson C; Alaupovic P
Perit Dial Int; 2002; 22(2):220-8. PubMed ID: 11990407
[TBL] [Abstract][Full Text] [Related]
2. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
[TBL] [Abstract][Full Text] [Related]
3. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
Kimak E; Solski J; Janicka L; Ksaziek A; Janicki K
Clin Chem Lab Med; 2000 May; 38(5):421-5. PubMed ID: 10952225
[TBL] [Abstract][Full Text] [Related]
4. The compositional abnormalities of lipoproteins in diabetic renal failure.
Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P
Nephrol Dial Transplant; 1998 Nov; 13(11):2833-41. PubMed ID: 9829487
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
6. Lipid and apolipoproteins (ApoAI, ApoB, Apo CIII, ApoE) disturbance in hemodialysis (HD) and renal transplant (Tx) patients.
Janicki K; Solski J; Janicka L; Kimak E; Bednarek-Skublewska A; Stettner S; Molas G
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(1):459-66. PubMed ID: 16146031
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
[TBL] [Abstract][Full Text] [Related]
8. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation.
Hughes TA; Gaber AO; Amiri HS; Wang X; Elmer DS; Winsett RP; Hathaway DK; Hughes SM; Ghawji M
Metabolism; 1994 Mar; 43(3):333-47. PubMed ID: 8139482
[TBL] [Abstract][Full Text] [Related]
10. Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure.
Kimak E; Ksiazek A; Solski J
Clin Chem Lab Med; 2006; 44(1):64-9. PubMed ID: 16375588
[TBL] [Abstract][Full Text] [Related]
11. Effect of the combination of methyltestosterone and esterified estrogens compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density, and high density lipoproteins in surgically postmenopausal women.
Chiuve SE; Martin LA; Campos H; Sacks FM
J Clin Endocrinol Metab; 2004 May; 89(5):2207-13. PubMed ID: 15126543
[TBL] [Abstract][Full Text] [Related]
12. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.
Guan Y; Hou X; Tian P; Ren L; Tang Y; Song A; Zhao J; Gao L; Song G
Front Endocrinol (Lausanne); 2021; 12():646185. PubMed ID: 33967959
[TBL] [Abstract][Full Text] [Related]
13. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients.
Oi K; Hirano T; Sakai S; Kawaguchi Y; Hosoya T
Kidney Int Suppl; 1999 Jul; 71():S227-8. PubMed ID: 10412783
[TBL] [Abstract][Full Text] [Related]
14. Ability of non-high-density lipoprotein cholesterol and calculated intermediate-density lipoprotein to identify nontraditional lipoprotein subclass risk factors in dialysis patients.
Belani SS; Goldberg AC; Coyne DW
Am J Kidney Dis; 2004 Feb; 43(2):320-9. PubMed ID: 14750098
[TBL] [Abstract][Full Text] [Related]
15. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
[TBL] [Abstract][Full Text] [Related]
16. Statins for treatment of dyslipidemia in chronic kidney disease.
Shurraw S; Tonelli M
Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
19. Utility of non-high-density lipoprotein cholesterol in hemodialyzed patients.
Schreier L; González AI; Elbert A; Berg G; Wikinski R
Metabolism; 2004 Aug; 53(8):1013-5. PubMed ID: 15281010
[TBL] [Abstract][Full Text] [Related]
20. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.
Ikejiri A; Hirano T; Murayama S; Yoshino G; Gushiken N; Hyodo T; Taira T; Adachi M
Metabolism; 2004 Sep; 53(9):1113-7. PubMed ID: 15334369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
